MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Medpace Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 22, 2026

$619.66+1.19 (+0.19%)

Close on Oct 19, 2026

Market cap: $17.69B
P/E (TTM): 36.3
Dividend yield: –

Medpace Holdings, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	2,530	2,109	1,886	1,460	1,142	926	861	705	436	422	359
Selling, General & Admin	198	180	161	131	108	92	95	76	63	62	57
Advertising Expenses	1.50	1.50	1.50	1.30	–	–	–	–	–	–	–
Total Costs & Expenses	1,995	1,662	1,549	1,181	944	759	734	604	371	369	338
Operating Income	535	447	337	279	199	167	127	101	65	52	21
Other Non-Operating Income	7.44	29	-1.14	4.16	3.24	1.49	-2.43	-7.10	-7.91	-31	-28
Asset Impairment Charges	–	–	–	–	–	–	–	–	0	0	9.31
Pretax Income	542	476	336	283	202	169	125	94	57	22	-7.83
Income Tax Expense	91	72	53	37	20	23	24	21	18	8.53	0.84
Net Income incl. Noncontrolling Interests	–	–	–	245	182	145	100	73	39	13	–
Net Income	451	404	283	245	182	145	100	73	39	13	-8.67
Net Income to Common	451	404	283	245	181	145	100	73	39	13	-8.67
EPS (Basic)(per share)	15.64	13.06	9.20	7.57	5.06	4.07	2.79	2.05	1.00	0.38	-0.28
EPS (Diluted)(per share)	15.28	12.63	8.88	7.28	4.81	3.84	2.67	1.97	0.98	0.37	-0.28
Shares Outstanding (Basic, Weighted)(shares)	29	31	31	32	36	36	36	36	39	36	31
Shares Outstanding (Diluted, Weighted)(shares)	30	32	32	34	38	38	38	37	40	36	31

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 21.0%
Net margin: 17.7%
Return on equity, FY2025: 70.2%

Financial strength

Current ratio: 0.73
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 35.0%

Valuation

P/E ratio: 36.3
Price to sales: 6.36
Price to book: 40.78
Dividend yield: –